NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
6 trialsNCT04594187 2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04242329 2024-01-26
SUMMIST
Vastra Gotaland Region
Phase 2 Withdrawn
NCT02054520 2023-04-18
Immunotherapy Study for Patients With Stage IV Melanoma
Lumos Pharma
Phase 2 Terminated
NCT05077280 2022-12-06
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
Phase 2 Recruiting
NCT00101166 2018-02-28
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed